Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 138, 35-42
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca Australia
- Ono Pharmaceutical
- Bristol-Myers Squibb
- Japan Agency for Medical Research and Development
- Chugai Pharmaceutical
This publication has 55 references indexed in Scilit:
- The clinical significance of SWI/SNF complex in pancreatic cancerInternational Journal of Oncology, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- The tumour suppressor and chromatin‐remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancerEMBO Molecular Medicine, 2012
- Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot AssessmentJournal of Cancer, 2012
- Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor typesHuman Mutation, 2011
- Tissue Microarray Validation: A Methodologic Study with Special Reference to Lung CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- The Biology of Chromatin Remodeling ComplexesAnnual Review of Biochemistry, 2009
- RhoA-Dependent Regulation of Cell Migration by the Tumor Suppressor hSNF5/INI1Cancer Research, 2008
- Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expressionOncogene, 2002
- The BRG-1 Subunit of the SWI/SNF Complex Regulates CD44 ExpressionJournal of Biological Chemistry, 2001